Latest Drug Approval Process News

Paradigm Biopharmaceuticals has completed enrolment ahead of schedule in its pivotal Phase 3 trial for Zilosul®, enrolling 538 patients with knee osteoarthritis and maintaining its timeline for interim and final results.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.